Today's Breaking News
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseRead more
Latest R&D and Business News
28 March 2024
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program28 March 2024
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNewsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe2023 Sales of Antibodies & Proteins
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports